SB939

SB939 (also known as Pracinostat) is a histone deacetylase inhibitor (HDAC inhibitor) that is used in cancer research. It is a type of epigenetic therapy that has shown promise in preclinical and clinical trials for various types of cancer.

History

SB939 was developed by S*BIO, a biotechnology company based in Singapore. The company specializes in the discovery and development of novel small molecule drugs for the treatment of cancer.

Mechanism of Action

As a histone deacetylase inhibitor, SB939 works by blocking the action of histone deacetylases (HDACs). These are enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more tightly. This process is known as histone deacetylation, which is a type of epigenetic modification that can regulate gene expression.

By inhibiting the action of HDACs, SB939 can increase the acetylation of histones, leading to a more relaxed DNA structure. This can result in increased gene expression, which can inhibit the growth of cancer cells and induce cell death (apoptosis).

Clinical Trials

SB939 has been tested in several clinical trials for various types of cancer, including leukemia, multiple myeloma, and solid tumors. The results of these trials have shown that SB939 can have a significant anti-tumor effect, with some patients experiencing complete or partial responses.

Side Effects

Like all drugs, SB939 can have side effects. The most common side effects reported in clinical trials include fatigue, nausea, vomiting, and diarrhea. However, these side effects are generally manageable and do not lead to treatment discontinuation.

Future Directions

Research is ongoing to further understand the potential of SB939 in cancer treatment. This includes exploring its use in combination with other therapies, as well as investigating its potential in other types of cancer.